Veille documentaire MTPH

Auteur     Michael G. Bruce
Auteur     Dana Bruden
Auteur     Debby Hurlburt
Auteur     Carolyn Zanis
Auteur     Gail Thompson
Auteur     Lisa Rea
Auteur     Michele Toomey
Auteur     Lisa Townshend-Bulson
Auteur     Karen Rudolph
Auteur     Lisa Bulkow
Auteur     Philip R. Spradling
Auteur     Richard Baum
Auteur     Thomas Hennessy
Auteur     Brian J. McMahon
Volume     214
Numéro     1
Pages     16-22
Publication     The Journal of Infectious Diseases
ISSN     1537-6613
Date     Jul 01, 2016
Résumé     BACKGROUND: The duration of protection in children and adults resulting from hepatitis B vaccination is unknown. In 1981, we immunized a cohort of 1578 Alaska Native adults and children from 15 Alaska communities aged ≥6 months using 3 doses of plasma-derived hepatitis B vaccine. METHODS: Persons were tested for antibody to hepatitis B surface antigen (anti-HBs) levels 30 years after receiving the primary series. Those with levels <10 mIU/mL received 1 booster dose of recombinant hepatitis B vaccine 2-4 weeks later and were then evaluated on the basis of anti-HBs measurements 30 days after the booster. RESULTS: Among 243 persons (56%) who responded to the original primary series but received no subsequent doses during the 30-year period, 125 (51%) had an anti-HBs level ≥10 mIU/mL. Among participants with anti-HBs levels <10 mIU/mL who were available for follow-up, 75 of 85 (88%) responded to a booster dose with an anti-HBs level ≥10 mIU/mL at 30 days. Initial anti-HBs level after the primary series was correlated with higher anti-HBs levels at 30 years. CONCLUSIONS: Based on anti-HBs level ≥10 mIU/mL at 30 years and an 88% booster dose response, we estimate that ≥90% of participants had evidence of protection 30 years later. Booster doses are not needed.